CARDS 9
Normal Hematologic Values and Blood Component Overview
Erythrocytes (Red Blood Cells / RBCs):
Normal Reference Range (Males):
Normal Reference Range (Females):
Primary Function: Transport oxygen from the lungs to peripheral tissues via hemoglobin molecules attached to the red blood cell surface.
Hemoglobin (Hgb):
Normal Reference Range
Normal Reference Range (Females):
Hematocrit (Hct):
Normal Reference Range (Males):
Normal Reference Range (Females):
Leukocytes (White Blood Cells / WBCs):
Normal Reference Range:
Classification: Subdivided into granulocytes (neutrophils, eosinophils, basophils) and agranulocytes (lymphocytes, monocytes).
Thrombocytes (Platelets):
Normal Reference Range:
Primary Function: Hemostasis and blood clot formation.
General Concepts and Pathophysiology of Anemia
Definition: Anemia is defined as a reduction in the circulating quantity of red blood cells, resulting in a corresponding decrease in hemoglobin and hematocrit concentrations.
Pathophysiology & Compensatory Mechanisms:
Hemoglobin binds oxygen to RBCs for cellular delivery. Decreased hemoglobin reduces tissue oxygen delivery.
To maintain oxygenation to vital organs, the peripheral circulatory system compensates by shunting blood away from peripheral tissues toward central vital organs.
Shunting blood away from non-essential regions causes localized peripheral tissue hypoxia.
General Clinical Manifestations:
Cardiopulmonary & Musculoskeletal: Generalized fatigue, shortness of breath (dyspnea), and muscular weakness.
Acute Onset (e.g., severe hemorrhage): Manifests with sudden, dramatic, and severe clinical instability.
Chronic Onset (e.g., pernicious anemia): Onset is insidious. Patients display mild or non-dramatic symptoms such as general malaise, exertion-induced dyspnea, or heart palpitations; chronic anemia is frequently identified incidentally during routine laboratory evaluations.
General Etiologies:
Acute or chronic blood loss (e.g., active hemorrhage, menorrhagia, gastrointestinal bleeding).
Bone marrow suppression (impaired erythrocyte production).
Hemolysis (premature destruction of circulating erythrocytes).
Nutritional deficiencies (specifically iron, vitamin B12, or folic acid).
Hypovolemic Anemia (Blood Loss Anemia)
Etiology & Pathophysiology:
Results from acute or severe loss of circulating blood volume, which decreases overall circulating hemoglobin and oxygen-carrying capacity.
A rapid blood loss of or greater leads to severe hemodynamically unstable complications.
Common Causes: Internal or external hemorrhage, surgical blood loss, gastrointestinal (GI) bleeding, severe menorrhagia, traumatic injury, and extensive burns.
Clinical Manifestations & Assessment Findings:
Visible external hemorrhage or signs of occult internal bleeding.
Restlessness, anxiety, and irritability.
Subtle initial elevation in respiratory rate, progressing to rapid respirations.
Generalized weakness, confusion, or stupor.
Skin Changes: Pale (pallor), cool, and moist/clammy skin due to peripheral vasoconstriction and blood shunting.
Cardiovascular: Rapid, weak, and thready peripheral pulses; progressive hypotension.
Renal: Oliguria (decreased urine output due to impaired renal perfusion).
Neurological: Mental disorientation, lightheadedness, syncope.
Pain Manifestations: Internal bleeding can compress peripheral nerves, distend tissue spaces, and displace organs, causing severe localized or diffuse pain.
Pediatric Considerations: Children often remain compensate and asymptomatic initially, followed by rapid, sudden hemodynamic deterioration into deep hypovolemic shock.
Progression to Shock: Hypovolemic shock ensues when blood loss deprives organs of minimal oxygen and vital nutrients. The extent of heart rate elevation and blood pressure drop directly correlates with total volume lost.
Diagnostic Testing:
Acute Blood Loss Delay: Following acute hemorrhage, initial RBC, hemoglobin, and hematocrit levels may not immediately reflect the volume lost; it takes for fluid shifts to stabilize and reflect reduced RBC, Hgb, and Hct values.
Medical Management & Pharmacology:
Primary Goal: Rapidly identify and arrest the source of hemorrhage.
Fluid Resuscitation: Immediate administration of intravenous (IV) crystalloid fluids.
Blood Transfusion Therapy: Indicated when fluid resuscitation is insufficient or when hemoglobin drops below .
Transfusion Rule of Thumb: Administration of of packed red blood cells (PRBCs) increases circulating hemoglobin by and raises hematocrit by .
Pharmacology: Oral or parenteral iron supplementation to stimulate bone marrow erythropoiesis during recovery.
Nursing Interventions:
Continuously monitor active blood loss and maintain IV fluid/transfusion access.
Apply direct pressure or interventions to control active bleeding.
Position the patient supine and flat; keep the patient warm with blankets. Avoiding cold prevents peripheral vasoconstriction, which would further compromise peripheral perfusion.
Obtain vital signs every .
Implement safety precautions to prevent falls and physical injury secondary to disorientation or syncope.
Maintain strict Intake and Output (I&O) measurements to monitor for renal hypoperfusion.
Pernicious Anemia
Pathophysiology:
An autoimmune disorder causing impaired gastrointestinal absorption of Vitamin B12 (cobalamin).
Parietal cells within the gastric mucosa secrete intrinsic factor (IF), a glycoprotein required for Vitamin B12 absorption in the terminal ileum. Autoantibodies destroy gastric parietal cells or bind directly to intrinsic factor, causing an absolute lack of IF and subsequent Vitamin B12 deficiency.
Vitamin B12 is mandatory for nucleoprotein synthesis, cell maturation, normal erythrocyte maturation, and myelin maintenance in the nervous system. B12 deficiency results in macrocytic erythrocyte formation and progressive degeneration of peripheral nerves and spinal cord white matter.
Clinical Manifestations & Assessment Findings:
General Anemic Signs: Fatigue, weakness, restlessness, pallor.
Oral & Gastrointestinal: Smooth, erythematous, thick, tender, burning tongue (glossitis); nausea, vomiting, anorexia, flatulence, constipation, diarrhea, indigestion, and dysphagia.
Neurological Symptoms: Symmetrical paresthesia (numbness and tingling) in the hands and feet, loss of vibration sense, loss of proprioception (body position sense), visual alterations, cognitive dysfunction, memory loss, confusion, personality alterations, severe behavioral changes, and eventual paralysis if untreated.
Diagnostic Testing:
Complete Blood Count (CBC): Reduced RBC count, low Hgb, and low Hct. Elevated Mean Corpuscular Volume (MCV), indicating macrocytic (abnormally large) erythrocytes.
Reticulocyte Count: Low, reflecting reduced bone marrow production of new erythrocytes.
Serum Folate and Iron Levels: Measured to rule out co-existing deficiencies.
Bone Marrow Aspiration: Demonstrates megaloblastic erythroid hyperplasia.
Gastric Juice Analysis: Confirms the complete absence of free hydrochloric acid and absence of intrinsic factor in gastric secretions.
Serologic Autoantibody Testing: Positive tests for Intrinsic Factor Antibodies (first-line diagnostic test) and Gastric Parietal Cell Antibodies.
Medical Management & Pharmacology:
Vitamin B12 Replacement: Oral B12 replacement is ineffective for pernicious anemia caused by lack of intrinsic factor because the fundamental pathology is absorption failure, not dietary lack. Intramuscular (IM) injection therapy is required.
Standard IM Dosing Schedule: () of cyanocobalamin or hydroxycobalamin IM daily for (or for ), followed by weekly injections until hematocrit normalizes, and maintained with monthly IM injections for life.
Severe Neurological Symptoms Dosing Schedule: IM every other day until clinical neurological improvement occurs.
Prognosis without Treatment: Untreated pernicious anemia is fatal within .
Co-administration Rules: Folic acid or iron supplements are added if concurrent deficiencies exist. Critical Rule: Vitamin B12 deficiency MUST be corrected before initiating folic acid therapy. Administering folic acid alone to a B12-deficient patient resolves the hematologic abnormalities while allowing irreversible neurological damage (Subacute Combined Degeneration of the spinal cord) to progress rapidly.
Transfusion: PRBCs are administered in severe, hemodynamically unstable cases.
Nursing Interventions & Patient Teaching:
Assess vital signs every .
Provide frequent, gentle oral hygiene using soft swabs to soothe tender oral mucosa.
Dietary Management: Encourage a diet rich in high-protein foods, vitamins, and minerals including red meat, dairy products, and eggs (foods high in Vitamin B12).
Thermal Protection: Provide extra warm blankets and maintain a warm ambient room temperature; avoid hot water bottles or heating pads due to sensory paresthesias and burn risk.
Energy Conservation: Structure daily activities with planned rest periods; serve small, frequent, high-calorie meals.
Monitor bowel movements, noting stool color and consistency (especially when receiving concurrent iron therapy).
Patient Education: Emphasize that lifelong, uninterrupted monthly Vitamin B12 injection therapy is strictly required for survival.
Aplastic Anemia
Pathophysiology:
A severe, life-threatening disorder characterized by bone marrow aplasia or hypoplasia, resulting in pancytopenia (a profound reduction or complete destruction of all three major formed cellular elements of blood: erythrocytes, leukocytes, and thrombocytes).
Etiologies:
Autoimmune-mediated destruction of hematopoietic stem cells.
Infectious Agents: Viral hepatitis, Epstein-Barr virus (EBV), human immunodeficiency virus (HIV).
Physiologic Stressors: Pregnancy.
Exogenous Toxins & Therapies: Radiation therapy, antineoplastic chemotherapy drugs, toxic chemicals (pesticides, benzene, arsenic).
Clinical Manifestations & Assessment Findings:
Erythrocyte Suppression Symptoms: Profound fatigue, exertional dyspnea, dizziness, persistent cephalalgia, cool pale skin, tachycardia, and angina.
Leukocyte/Neutrophil Suppression Symptoms: High fevers, recurrent or lingering systemic infections, frequent flu-like illnesses, and oral mucosal ulcerations.
Thrombocyte Suppression Symptoms: Epistaxis, mucosal bleeding, bleeding gums, petechiae, ecchymosis, blood in stool (hematochezia or melena), and severe menorrhagia.
Patient Assessment: Review history for exposure to industrial chemicals or bone marrow-depressing medications. Assess functional ability to complete Activities of Daily Living (ADLs) without severe fatigue.
Diagnostic Testing:
CBC: Marked decrease in all cell lines (anemia, leukopenia, neutropenia, thrombocytopenia).
Reticulocyte Count: Extremely low or absent.
Bone Marrow Aspiration and Biopsy: Shows severe hypocellularity, fat replacement of hematopoietic marrow space, and low counts of RBC, WBC, and platelet precursors.
Medical Management & Pharmacology:
Etiologic Intervention: Identify and immediately remove or discontinue exposure to the causative toxic agent or medication.
Blood Component Therapy: Avoid unnecessary blood transfusions to prevent the development of human leukocyte antigen (HLA) sensitization, which increases the risk of bone marrow transplant rejection.
Pharmacology: Corticosteroids and synthetic androgens are administered to stimulate residual bone marrow stem cell hematopoiesis.
Splenectomy: Indicated if the spleen is sequestering or destroying healthy circulating platelets and erythrocytes.
Hematopoietic Stem Cell Transplantation (HSCT): Primary definitive cure, most successful in patients under of age.
Nursing Interventions:
Infection Control: Enforce strict neutropenic precautions. Maintain strict sterile aseptic technique for all central line dressings, IV access, and wound care. Restrict visitors with active illnesses.
Bleeding Prevention: Strictly avoid intramuscular (IM) injections, rectal medications, and rectal temperature measurements to prevent severe mucosal and intramuscular hemorrhage.
Skin Integrity: Use specialized pressure-reducing air mattresses to prevent skin breakdown and pressure ulceration.
Observation: Monitor continuously for subtle signs of active bleeding and early systemic infection.
Iron Deficiency Anemia
Pathophysiology:
A condition in which red blood cells contain abnormally reduced concentrations of hemoglobin due to insufficient elemental iron, which is required for the heme synthesis component of hemoglobin.
Erythrocytes appear microcytic (abnormally small) and hypochromic (pale).
Etiologies:
Chronic, excessive blood loss: Gastrointestinal bleeding secondary to peptic or duodenal ulcer disease, esophageal varices, or diverticulosis; chronic menorrhagia.
Dietary inadequacy: Diets deficient in iron-rich foods.
Malabsorption states or B12 non-absorption.
High-risk Populations: Most prevalent in young children, growing adolescents, women of childbearing age, and pregnant women.
Clinical Manifestations & Assessment Findings:
General Symptoms: Pallor, persistent fatigue, generalized weakness, exertional dyspnea, cold sensitivity, cold extremities, and non-cardiac chest pain.
Oral & Mucosal: Glossitis (inflammation, redness, and swelling of the tongue), stomatitis, and dry, cracked lips (cheilitis).
Pica/Pagophagia: Compulsive craving and ingestion of non-food substances or ice, clay, and starches.
Dermatologic/Nail Changes: Fragile, brittle, spoon-shaped fingernails featuring a central longitudinal depression and raised lateral borders (koilonychia).
Diagnostic Testing:
CBC: Decreased RBC count, hemoglobin, and hematocrit; low Mean Corpuscular Volume (MCV).
Serum Iron Metrics: Significantly reduced serum iron and elevated Total Iron-Binding Capacity (TIBC).
Medical Management & Pharmacology:
Iron Supplementation Routes:
Oral: Ferrous sulfate.
Intramuscular (IM): Iron dextran (administered using the Z-track injection method to prevent subcutaneous tissue staining).
Intravenous (IV): Iron sucrose.
Adverse Effects of Iron Therapy: Gastrointestinal irritation including nausea, heartburn, abdominal cramps, diarrhea, constipation, and dark or tarry black stool coloration.
Pharmacologic Interactions:
Absorption Enhancers: Vitamin C (ascorbic acid) and oral contraceptive agents increase iron absorption.
Absorption Inhibitors: Antacids, cholesterol-lowering agents (e.g., cholestyramine), and calcium/dairy products significantly decrease iron absorption.
Administration Guidelines: Administer oral iron supplements at least before or after meals to maximize absorption. Never administer oral iron with milk or dairy products.
Monitoring: Serial CBC re-evaluation every .
Nursing Interventions & Patient Teaching:
Structure daily activities to include essential rest intervals between exertions.
Dietary Teaching: Educate patients to consume iron-dense foods such as dark leafy green vegetables, egg yolks, liver, organ meats, shellfish, and iron-fortified cereals and breads.
Reassure the patient that iron therapy alters stool color to dark green or black, preventing unnecessary alarm.
Sickle Cell Anemia
Pathophysiology & Genetics:
An autosomal recessive genetic disorder characterized by the synthesis of an abnormal hemoglobin S (HbS) molecule within erythrocytes.
When exposed to low oxygen tensions, deoxygenated HbS molecules polymerize, causing red blood cells to lose their flexible biconcave disc shape and assume a rigid, elongated crescent or sickle shape.
Sickled RBCs have a significantly shortened lifespan of , compared to normal RBCs which circulate for .
The disorder is severe, chronic, incurable, and predominantly affects individuals of African or Eastern Mediterranean descent.
Sickle Cell Trait vs. Sickle Cell Disease:
Sickle Cell Trait: Inheritance of one mutated HbS gene from one parent and one normal HbA gene from the other parent. Trait carriers are asymptomatic, display no clinical illness, and lead normal lives. A carrier cannot develop sickle cell disease.
Sickle Cell Disease: Inheritance of the mutated HbS gene from both parents.
Sickle Cell Crisis (Vaso-Occlusive Crisis):
Pathogenesis: Rigid, sickled erythrocytes aggregate and adhere to microvascular endothelium, forming microthrombi that obstruct blood flow.
Vascular occlusion causes downstream tissue ischemia, cellular hypoxia, tissue necrosis, and severe localized or systemic pain.
Precipitating Triggers: Dehydration, systemic infection, physical overexertion, weather/temperature extremes (especially exposure to cold), alcohol ingestion, smoking, emotional stress, and high altitudes.
Clinical Manifestations & Assessment Findings:
Infant Onset: Newborns are asymptomatic for the first of life due to protective circulating levels of fetal hemoglobin (HbF).
Pain Characteristics during Crisis: Continuous, excruciating, deep, gnawing, and throbbing pain localized primarily in the back, abdomen, long bones, and joint spaces (hands and feet/dactylitis).
Abdominal & Organ Changes: Abdominal distension and pain secondary to visceral pooling of blood in the liver and spleen (splenomegaly/hepatomegaly).
Systemic Findings: Jaundice (from chronic hemolysis), extremity edema, organ infarction, multi-system organ failure, and retinal vascular damage leading to blindness.
Acute Chest Syndrome: A life-threatening complication resulting from sickling within pulmonary vasculature, impairing alveolar gas exchange. Manifests as sudden chest pain, fever, tachypnea, severe dyspnea, hypoxemia, and cough.
Diagnostic Testing:
Hemoglobin Electrophoresis: Identifies and quantifies the exact percentage of Hemoglobin S (HbS) versus normal Hemoglobin A (HbA).
CBC: Low hemoglobin and hematocrit; elevated WBC count (leukocytosis is common, especially during vaso-occlusive crises or active infections).
Skeletal Radiographs: Demonstrates bone deformities, cortical thinning, and joint destruction.
Medical Management & Pharmacology:
Acute Vaso-Occlusive Crisis Protocol: Aggressive IV fluid rehydration to decrease blood viscosity, supplemented by continuous oxygenation.
Analgesic Management: Mild crises are managed with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Severe crises require immediate, high-dose IV opioids (e.g., morphine or hydromorphone) administered at scheduled intervals or via Patient-Controlled Analgesia (PCA).
Pharmacology: Hydroxyurea increases production of fetal hemoglobin (HbF), reducing the frequency of sickling episodes and painful crises. Folic acid supplements are given to support elevated erythropoiesis.
Infection Control: Aggressive, prompt parenteral antibiotic therapy for suspected infections.
Advanced Interventions: PRBC transfusions or exchange transfusions. Hematopoietic stem cell transplantation represents the only potential curative intervention.
Nursing Interventions & Patient Teaching:
Administer high-volume IV crystalloid hydration to dilute intravascular sickled cellular aggregates.
Provide prompt, scheduled analgesia; do not delay pain medication administration during active vaso-occlusive crises.
Educate the patient to strictly avoid known precipitating triggers: high altitudes, unpressurized aviation, cold ambient temperatures, iced beverages, alcohol, smoking, vigorous exhaustive exercise, and dehydration.
Encourage full adherence to recommended immunization schedules (including pneumococcal and meningococcal vaccines) to prevent precipitating infections.
Perform gentle, passive range-of-motion exercises and protect inflamed, painful joints.
Polycythemia Vera
Pathophysiology:
A chronic myeloproliferative neoplasm characterized by bone marrow hyperplasia (overgrowth).
Leads to uncontrolled overproduction of erythrocytes, granulocytes, basophils, and thrombocytes.
The excessive cellular mass increases total blood volume and expands blood viscosity (hyperviscosity), causing sluggish intravascular flow, tissue/organ vascular congestion, hypercoagulopathy, and a high risk of vascular thrombosis and organ infarction.
Clinical Manifestations & Assessment Findings:
Thrombotic Complications: High incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), and ischemic stroke.
Vascular & Bleeding Manifestations: Esophageal varices, epistaxis, gastrointestinal bleeding, and petechiae (caused by distended venous channels and intrinsic platelet dysfunction).
Organ Involvement: Splenomegaly and hepatomegaly secondary to major organ engorgement.
Sensory & Neurological: Cephalalgia, vertigo, tinnitus, blurred vision, painful burning paresthesias in the extremities (erythromelalgia), and extreme thermal sensitivity to cold and hot.
Dermatologic: Facial redness/plethora, eczema, and severe generalized pruritus (itching) that is typically aggravated by warm baths or showers (aquagenic pruritus), caused by excess basophil histamine release.
Diagnostic Testing:
CBC: Elevated RBC count, Hgb, Hct, WBC count, and platelet count.
Serum Metrics: Elevated serum histamine, elevated leukocyte alkaline phosphatase, elevated serum uric acid, and an increased Basal Metabolic Rate (BMR).
Medical Management & Pharmacology:
Therapeutic Phlebotomy: Primary treatment involving initial periodic removal of of blood until hematocrit is maintained within . Phlebotomy is repeated whenever hematocrit exceeds .
Myelosuppressive Therapy: Administered to inhibit marrow cellular production. Agents include hydroxyurea, busulfan, and melphalan.
Nursing Interventions:
Avoid fluid volume overload, which worsens circulatory congestion.
Avoid dehydration, which increases blood hyperviscosity and precipitates thrombotic events.
Nutritional Support: Provide high-calorie nutrition to match the elevated BMR, accounting for GI distress.
Activity: Maintain regular, low-impact physical activity to prevent venous stasis and thrombus formation.
Agranulocytosis
Pathophysiology:
A severe hematologic condition characterized by a critical reduction in circulating granulocytes (neutrophils, basophils, eosinophils), causing profound leukopenia and absolute neutropenia.
Leaves the host extremely vulnerable to severe, opportunistic bacterial and fungal infections.
Etiologies:
Adverse drug toxicity or hypersensitivity reactions. High-risk medications include penicillins, captopril, ranitidine, and antithyroid agents.
Cytotoxic chemotherapy and ionizing radiation therapy.
Neoplastic bone marrow diseases and severe viral or bacterial systemic infections.
Clinical Manifestations & Assessment Findings:
Infectious Signs: Sudden onset of high fever, chills, severe headache, malaise, and extreme physical weakness progressing rapidly to prostration (total exhaustion and collapse).
Mucosal Lesions: Ulcerative lesions on the mucous membranes of the mouth (pharyngitis, stomatitis), nose, vagina, and rectum.
Systemic Infection Progression: Late-stage development of severe bacterial pneumonia and urinary tract infections (UTIs).
Auscultation Findings: Adventitious pulmonary breath sounds including crackles and rhonchi.
Diagnostic Testing:
CBC with Differential: Markedly low total leukocyte count with severe, absolute neutropenia.
Microbiological Cultures: Blood, wound, and mucosal ulcer cultures to isolate causative infectious agents.
Bone Marrow Biopsy: Reveals dramatic depression or complete absence of granulocytic precursor cells.
Medical Management & Pharmacology:
Immediate discontinuation of potential causative offending medications.
Empiric and targeted broad-spectrum parenteral antibiotic therapy based on culture results.
Administration of PRBCs as indicated.
Initiation of Neutropenic Precautions.
Nursing Interventions:
Monitor body temperature continuously; fever is an immediate medical emergency.
Enforce Protective/Neutropenic Isolation Precautions: Restrict all visitors with infectious signs, ban fresh flowers, live plants, and standing water in the patient's room.
Enforce hand hygiene before entering the patient's room.
Dietary Management: Provide cooked foods high in protein, vitamins, and calories. Strictly ban all raw fruits, raw vegetables, unpasteurized dairy, and undercooked meats to prevent exposure to pathogens. Encourage high fluid intake.
Provide gentle, non-traumatic oral hygiene.
Educate the patient to avoid crowded public places and individuals with active infections.
Thrombocytopenia and Immune Thrombocytopenic Purpura
Pathophysiology:
A deficiency of circulating platelets below the normal threshold of , resulting in impaired primary hemostatic plug formation and an increased risk of bleeding.
Immune Thrombocytopenic Purpura (ITP): An autoimmune condition in which anti-platelet autoantibodies coat circulating platelets. Although antibody-coated platelets function normally, they are recognized as foreign by splenic macrophages and destroyed prematurely.
Platelet Lifespan Reduction: Normal platelets circulate for ; in ITP, platelet lifespan is reduced to .
Etiologies:
Autoimmune mechanisms (ITP), acute viral infections, drug-induced immune reactions, or direct marrow suppression.
Clinical Manifestations & Assessment Findings:
Cutaneous Manifestations: Petechiae (pinpoint, non-blanching, flat red or purple hemorrhagic spots on the skin) and ecchymosis (larger purple subcutaneous hemorrhages/bruising).
Mucosal Hemorrhage: Epistaxis, gingival bleeding, hematemesis, melena, hematuria, and menorrhagia.
Neurological Assessment: Monitor closely for subtle signs of increased intracranial pressure (ICP), which indicates acute, fatal intracranial hemorrhage.
Diagnostic Testing:
CBC: Platelet count below .
Coagulation Parameters: Prolonged bleeding time; Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) typically remain normal.
Bone Marrow Analysis: Demonstrates normal or increased numbers of megakaryocytes (immature platelet precursors) attempting bone marrow compensation.
Medical Management & Pharmacology:
Pharmacology: Systemic corticosteroids are first-line therapy for autoimmune ITP to suppress splenic macrophage phagocytosis. Intravenous Immunoglobulin (IVIG) is administered to block macrophage Fc receptors.
Transfusion Therapy: Transfusion of concentrated platelets or PRBCs during active hemorrhage.
Surgical Management: Splenectomy is indicated if pharmacological suppression fails, eliminating the primary site of platelet destruction.
Nursing Interventions & Patient Teaching:
Monitor platelet counts and clinical bleeding times continuously.
Bleeding Precautions: Handle the patient gently, avoid invasive procedures, eliminate IM injections, avoid rectal temperatures or suppositories, and apply direct pressure to venipuncture sites for at least .
Instruct the patient to use a soft-bristled toothbrush, avoid razor blades (use electric razors only), and blow the nose gently.
Dietary Management: High-fiber diet and stool softeners to prevent straining during defecation, avoiding mucosal tears.
Monitor for systemic transfusion reactions during blood product administration.
Coagulation Disorders: Hemophilia and Von Willebrand Disease
Hemophilia Pathophysiology & Genetics:
An X-linked recessive hereditary coagulation disorder affecting predominantly males, with females acting as asymptomatic genetic carriers.
Characterized by an absolute deficiency or functional absence of specific plasma clotting factors, preventing intrinsic coagulation cascade progression and causing prolonged bleeding times.
Hemophilia A (Classic Hemophilia): Deficiency or functional absence of Factor VIII (accounts for the majority of hemophilia cases).
Hemophilia B (Christmas Disease): Deficiency or functional absence of Factor IX.
Clinical Manifestations of Hemophilia:
Severe, persistent hemorrhage following minor physical trauma, small superficial cuts, or routine dental extractions.
Hemarthrosis: Bleeding directly into joint cavities (knees, ankles, elbows, shoulders, hips), which represents the hallmark clinical sign of severe hemophilia. Hemarthrosis causes severe localized pain, joint effusion/edema, erythema, localized warmth, and progressive joint deformity/ankylosis.
Deep tissue hematomas, hematuria, and gastrointestinal bleeding.
Diagnostic Findings in Hemophilia:
Specific Factor Assays: Factor VIII or Factor IX activity levels are low or absent.
Coagulation Panel: Partial Thromboplastin Time (PTT) is significantly prolonged. Platelet count, Prothrombin Time (PT), and International Normalized Ratio (INR) are normal.
Medical Management & Factor Replacement in Hemophilia:
Cryoprecipitate: Contains Factor VIII. Historically used, but currently restricted due to high risks of viral pathogen transmission (e.g., HIV, Hepatitis) from human pooled plasma, and the requirement for low-temperature storage (impractical for home use).
Human Plasma-Derived Factor VIII: Purified factor extracted from donor blood that undergoes viral inactivation processing.
Recombinant Factor VIII: Synthetic factor produced in laboratories via recombinant DNA technology. This is the treatment of choice because it carries zero risk of human viral transmission, presents low cost, and provides an unlimited supply.
Von Willebrand Disease Pathophysiology:
An inherited hemorrhagic disorder characterized by abnormally slow blood coagulation and spontaneous mucosal hemorrhage (epistaxis, GI bleeding, gingival bleeding).
Caused by a deficient or defective Von Willebrand Factor (vWF), a protein critical for platelet adhesion to damaged vascular subendothelium and for stabilizing Factor VIII in circulation.
Disease Variants: Type 1 (quantitative reduction in vWF), Type 2 (qualitative defect/abnormal function of vWF), Type 3 (total absence of vWF, most severe variant).
Medical Management of Von Willebrand Disease:
Desmopressin (DDAVP): A synthetic analog of vasopressin (antidiuretic hormone) that stimulates the release of endogenous vWF and Factor VIII from endothelial storage sites.
Factor Replacement: Administration of plasma concentrates containing purified vWF and Factor VIII.
Nursing Interventions for Hemophilia & Von Willebrand Disease:
Hemorrhage Control: Apply immediate direct pressure and local cold application/ice packs to active bleeding sites to promote localized vasoconstriction.
Pain Management: Administer prescribed analgesics during acute hemarthrosis. Absolute Contraindication: NEVER administer aspirin or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) because they inhibit platelet aggregation and exacerbate bleeding.
Joint Care: Mobilize joints only after acute bleeding stops; encourage non-weight-bearing range-of-motion exercises during rehabilitation.
Safety Precautions: Instruct patient to use soft toothbrushes, wear medical alert identification, and eliminate contact sports.
Disseminated Intravascular Coagulation (DIC)
Pathophysiology:
A complex, paradoxical hemorrhagic and thrombotic syndrome characterized by uncontrolled, hyper-stimulation of both normal clotting and fibrinolytic pathways.
Primary Phase: Widespread systemic activation of the coagulation cascade causes microvascular thrombosis throughout small capillary beds, leading to organ ischemia and tissue necrosis.
Secondary Phase: Excessive clot formation rapidly consumes all available circulating clotting factors (Factors V, VII, VIII, X, XI) and platelets. Simultaneously, secondary fibrinolysis breaks down existing clots, yielding high levels of circulating fibrin degradation products (FDPs) which exert direct anticoagulant effects. This leads to profound, uncontrolled systemic hemorrhage.
Etiologies:
Obstetrical Emergencies: Abruptio placentae, intrauterine fetal demise (retained dead fetus), delayed delivery, and severe preeclampsia.
Non-Obstetrical Triggers: Massive systemic sepsis, severe trauma, extensive burn injuries, and shock states.
Clinical Manifestations & Assessment Findings:
Simultaneous Thrombotic & Hemorrhagic Signs: Profuse bleeding from venipuncture sites, surgical incisions, or urinary/GI tracts, co-occurring with peripheral cyanosis and ischemia of distal digits.
Cutaneous Changes: Purpura on the chest and abdomen, representing capillary fibrin deposition, is the classic early clinical marker of DIC. Accompanied by petechiae, ecchymosis, and cold, mottled extremities.
Cardiopulmonary: Dyspnea, cough, hemoptysis, pulmonary edema, pulmonary embolism, severe hypotension, and tachycardia.
Renal & Musculoskeletal: Oliguria, acute kidney failure, diffuse bone and joint pain.
Neurological: Restlessness, severe confusion, vision changes, seizures, intracerebral hemorrhage, and coma.
Vascular: Absence or loss of peripheral arterial pulses.
Diagnostic Testing:
Coagulation Panel: Significantly prolonged Prothrombin Time (PT) and Partial Thromboplastin Time (PTT).
Platelet Count: Severely reduced (thrombocytopenia).
Fibrinogen Levels: Profoundly depleted.
Clotting Factor Assays: Demonstrated deficiency of Factors V, VII, VIII, X, and XI.
D-Dimer Assay: Significantly elevated, indicating high rates of intravascular fibrin degradation.
Medical Management & Pharmacology:
Etiologic Treatment: Promptly treat the underlying trigger (e.g., surgical delivery of the placenta/fetus, aggressive treatment of underlying sepsis).
Blood Product Replacement: Transfusion of fresh frozen plasma (FFP) to replace depleted clotting factors, platelet concentrates, and packed red blood cells (PRBCs).
Heparin Therapy: Administered cautiously in selected early-stage cases where microvascular thrombotic occlusion dominates and active overt bleeding is minimal, to block further consumption of clotting factors.
Nursing Interventions:
Monitor serial Hgb, Hct, platelet counts, coagulation panels, and D-dimer levels.
Assess skin, mucous membranes, venipuncture sites, surgical sites, and GI/urinary drainage continuously for active bleeding.
Perform neurological assessments, monitoring level of consciousness and vital signs for intracranial hemorrhage.
Eliminate all non-essential intramuscular injections and venipunctures. Apply direct, prolonged pressure to bleeding sites.
Trauma Prevention: Pad bed side rails, use non-traumatic foam or cotton swabs for oral care, strictly ban razor blades and hard toothbrushes, and instruct the patient to avoid forceful nose blowing.